Scott Werneke

1.1k total citations
10 papers, 456 citations indexed

About

Scott Werneke is a scholar working on Public Health, Environmental and Occupational Health, Infectious Diseases and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Scott Werneke has authored 10 papers receiving a total of 456 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Public Health, Environmental and Occupational Health, 3 papers in Infectious Diseases and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Scott Werneke's work include Mosquito-borne diseases and control (6 papers), interferon and immune responses (3 papers) and Autophagy in Disease and Therapy (3 papers). Scott Werneke is often cited by papers focused on Mosquito-borne diseases and control (6 papers), interferon and immune responses (3 papers) and Autophagy in Disease and Therapy (3 papers). Scott Werneke collaborates with scholars based in United States, France and Spain. Scott Werneke's co-authors include Matthew L. Albert, Deborah J. Lenschow, Pierre-Emmanuel Joubert, Lucie Peduto, Claire de la Calle, Florence Guivel‐Benhassine, Alessandra Giodini, Beth Levine, Olivier Schwartz and Dana L. Vanlandingham and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and The Journal of Cell Biology.

In The Last Decade

Scott Werneke

10 papers receiving 447 citations

Peers

Scott Werneke

PHEOH

IMMUN

EPIDE

Karla M. Viramontes United States

Hong-Jiang Wang China

Vidyanath Chaudhary Hong Kong

Ryan Swenerton United States

Roland Tschismarov Austria

Lisa J. Ioannidis Australia

Nan L. Li United States

Sumudu Narayana Australia

Lina Mouna France

Sumalee Jindadamrongwech Thailand

Karla M. Viramontes United States

Scott Werneke

243 ×1.1

PHEOH

211 ×1.3

97 ×0.6

IMMUN

82 ×0.6

EPIDE

54 ×0.6

Citations per year, relative to Scott Werneke Scott Werneke (= 1×) peers Karla M. Viramontes

Countries citing papers authored by Scott Werneke

Since Specialization

Citations

This map shows the geographic impact of Scott Werneke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott Werneke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott Werneke more than expected).

Fields of papers citing papers by Scott Werneke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott Werneke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott Werneke. The network helps show where Scott Werneke may publish in the future.

Co-authorship network of co-authors of Scott Werneke

This figure shows the co-authorship network connecting the top 25 collaborators of Scott Werneke. A scholar is included among the top collaborators of Scott Werneke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott Werneke. Scott Werneke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Abrams, Thomas A., Syed Mohammad Ali Kazmi, Ira Winer, et al.. (2022). A phase 1b multitumor cohort study of cabozantinib plus atezolizumab in advanced solid tumors (COSMIC-021): Results of the colorectal cancer cohort.. Journal of Clinical Oncology. 40(4_suppl). 121–121. 14 indexed citations

Neal, Joel W., Enriqueta Felip, Ryan D. Gentzler, et al.. (2021). FP14.08 Cabozantinib Plus Atezolizumab in NSCLC Patients Previously Treated with a Checkpoint Inhibitor: Results from COSMIC 021. Journal of Thoracic Oncology. 16(3). S230–S231. 4 indexed citations

McGregor, Bradley A., Neeraj Agarwal, Cristina Suárez, et al.. (2020). 709P Cabozantinib (C) in combination with atezolizumab (A) in non-clear cell renal cell carcinoma (nccRCC): Results from cohort 10 of the COSMIC-021 study. Annals of Oncology. 31. S558–S558. 10 indexed citations

Neal, Joel W., Farah Louise Lim, Enriqueta Felip, et al.. (2020). Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated with an immune checkpoint inhibitor: Results from cohort 7 of the COSMIC-021 study.. Journal of Clinical Oncology. 38(15_suppl). 9610–9610. 28 indexed citations

Webster, Brian, Scott Werneke, Biljana Zafirova, et al.. (2018). Plasmacytoid dendritic cells control dengue and Chikungunya virus infections via IRF7-regulated interferon responses. eLife. 7. 50 indexed citations

Werneke, Scott. (2013). A Role for Interferon Stimulated Gene-15 (ISG15) During Chikungunya Virus Infection. Open Scholarship Institutional Repository (Washington University in St. Louis). 1 indexed citations

Joubert, Pierre-Emmanuel, Scott Werneke, Claire de la Calle, et al.. (2012). Chikungunya-induced cell death is limited by ER and oxidative stress-induced autophagy. Autophagy. 8(8). 1261–1263. 36 indexed citations

Joubert, Pierre-Emmanuel, Scott Werneke, Claire de la Calle, et al.. (2012). Chikungunya virus–induced autophagy delays caspase-dependent cell death. The Journal of Cell Biology. 197(3). i5–i5. 4 indexed citations

Joubert, Pierre-Emmanuel, Scott Werneke, Claire de la Calle, et al.. (2012). Chikungunya virus–induced autophagy delays caspase-dependent cell death. The Journal of Experimental Medicine. 209(5). 1029–1047. 159 indexed citations

10.

Werneke, Scott, Clémentine Schilte, Anjali Rohatgi, et al.. (2011). ISG15 Is Critical in the Control of Chikungunya Virus Infection Independent of UbE1L Mediated Conjugation. PLoS Pathogens. 7(10). e1002322–e1002322. 150 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact